The case for assessing the full value of new tuberculosis vaccines

Eur Respir J. 2020 Mar 20;55(3):1902414. doi: 10.1183/13993003.02414-2019. Print 2020 Mar.

Authors

Nebiat Gebreselassie¹, Raymond Hutubessy², Johan Vekemans², Saskia den Boon², Tereza Kasaeva³, Matteo Zignol³

Affiliations

¹ Global TB Programme, World Health Organization, Geneva, Switzerland gebreselassien@who.int.
² Dept of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
³ Global TB Programme, World Health Organization, Geneva, Switzerland.

PMID: 32198269
DOI: 10.1183/13993003.02414-2019

No abstract available

Publication types

Editorial

MeSH terms

BCG Vaccine
Humans
Mycobacterium tuberculosis*
Tuberculosis Vaccines*
Tuberculosis* / diagnosis
Tuberculosis* / prevention & control

Substances

BCG Vaccine
Tuberculosis Vaccines

Grants and funding

001/WHO_/World Health Organization/International